Background Following the emergency use authorisation of the Pfizer–BioNTech mRNA
COVID-19 vaccine BNT162b2 (international non-proprietary name tozinameran) in Israel, the …

Vaccination after SARS-CoV-2 Infection Six patients previously infected with the original
SARS-CoV-2 virus received the BNT162b2 vaccine. Before vaccination, they had neutralizing …

Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2
messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 …

Background Approximately 5.1 million Israelis had been fully immunized against coronavirus
disease 2019 (Covid-19) after receiving two doses of the BNT162b2 messenger RNA …

Background In December 2020, Israel began a mass vaccination campaign against coronavirus
disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp …

Neutralization of Omicron with Third Vaccine Dose Serum samples from 20 participants who
had received two doses of the BNT162b2 vaccine and from 20 who had received three …

Background Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
provides natural immunity against reinfection. Recent studies have shown waning of the …

Background On January 2, 2022, Israel began administering a fourth dose of BNT162b2
vaccine to persons 60 years of age or older. Data are needed regarding the effect of the fourth …

SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in
Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech…

Background After promising initial results from the administration of a third (booster) dose of
the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) to persons 60 years of age or …